TY - JOUR
T1 - Ameliorating effect of erythropoietin in a severe case of COVID-19
T2 - case report
AU - Maufak, Mais Mamoon
AU - Khan, Gulfaraz
AU - Purushothaman, Ani
AU - Ahamed, Fiaz
AU - Jallo, Mahir Khalil
AU - Rizwan, Mohammed
AU - Kumar, Sangeeth
AU - Almansouri, Ahmed
AU - Almansoori, Taleb Mohamed
AU - Ouseppachen, Megha Thottappillil
N1 - Publisher Copyright:
© Mais Mamoon Maufak et al.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the standard interventions and continued to deteriorate. On day 22 of his illness, after informed consent, the patient was administered 4000IU of erythropoietin (EPO) subcutaneously, in the hope of improving his O2 saturation. Positive response was observed in the patient within 24 hours. This prompted us to continued EPO treatment for a total of 42 days until full recovery and discharge. Our findings warrant further studies to ascertain the use of EPO in severe cases COVID-19.
AB - The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the standard interventions and continued to deteriorate. On day 22 of his illness, after informed consent, the patient was administered 4000IU of erythropoietin (EPO) subcutaneously, in the hope of improving his O2 saturation. Positive response was observed in the patient within 24 hours. This prompted us to continued EPO treatment for a total of 42 days until full recovery and discharge. Our findings warrant further studies to ascertain the use of EPO in severe cases COVID-19.
KW - COVID-19
KW - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
KW - acute respiratory distress syndrome (ARDS)
KW - case report
KW - erythropoietin
UR - http://www.scopus.com/inward/record.url?scp=85143763265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143763265&partnerID=8YFLogxK
U2 - 10.11604/pamj.2022.43.129.35014
DO - 10.11604/pamj.2022.43.129.35014
M3 - Article
C2 - 36762166
AN - SCOPUS:85143763265
SN - 1937-8688
VL - 43
JO - Pan African Medical Journal
JF - Pan African Medical Journal
M1 - 129
ER -
